Eiko Lifesciences Limited · BSE:EIKO
Eiko Lifesciences — Q3 FY2020-21 Earnings Presentation
19 slides from Eiko Lifesciences's earnings presentation, 2020
Slide 1: Investor's Presentation
INVESTOR’S PRESENTATION “Eiko LifeSciences” is a division of Narendra Investments (Delhi) Ltd., BSE Code: NIDL | 540204 |
Slide 2: Safe Harbor
SAFE HARBOR This presentation and the accompanying slides (the “Presentation”), which have been prepared by Eiko LifeSciences (a division of Narendra Investments (Delhi) Ltd.) (the “Company”), solely for information purposes and do not constitute any offer, recommendation or invitation to purchase o
Slide 3: The Ethos- Vision and Mission
The Ethos- Vision and Mission 3
Slide 4: About the Company
ABOUT THE COMPANY Narendra Investments (Delhi) Ltd. Incorporated in 1977 (BSE Code: NIDL | 540204 |) has recently ventured in the business of Manufacturing, Supplying and Export of Speciality & Fine Chemicals. Company has formed a separate division namely “Eiko LifeSciences” by amending the main obj
Slide 5: Company Overview
Company Overview 5
Slide 6: Company overview: speciality and fine chemicals offerings
In a short span of time, company has established itself in the race of becoming India's leading Speciality & Fine Chemicals Manufacturer, Supplier & Exporting company. ➢ Company’s Speciality Chemicals product offerings comprise of Organic as well as and Inorganic chemicals. ➢ Its products are used i
Slide 7: Q-3 FY 20-21 Financial Performance
Q-3 FY 20-21 Financial Performance 7
Slide 8: Financial Performance Highlights Q3 FY 20-21
Financial Performance Highlights Q3 FY 20-21 ➢ Company recorded revenue of ₹ 596.75 Lakhs in its first quarter of which ₹209.21 Lakhs was on account of exports and deemed exports ➢ The EBIDTA of the quarter is ₹ 31.32 Lakhs ➢ The PAT of the quarter is ₹ 24.35 Lakhs Highlights ➢ Company reported the
Slide 9: EGM Resolutions to venture into new business activities
Company passed Resolutions in the EGM held on 15 th December 2020 to venture in the New business activities 9
Slide 10: Alteration of main object and authorized share capital
Alteration of main object: 1. To carry on the business of manufacturing, processing, formulating, producing, refining, fermenting, converting, distilling, purifying, blending, buying, importing, stocking, supplying, selling, distributing, trading, exporting and dealing in all kinds and varieties of
Slide 11: Our Products & Business
Our Products & Business 11
Slide 12: Our Products Profile
OUR Products Profile 3-Chloropropiophenone Orthochlorobenzonitrile Saccharin/ Sodium saccharin (2-Chlorobenzonitrile) (benzoic sulfonamide) Key Starting intermediate for Pharmaceutical products such as Used as pharmaceutical Used as sweetener Bupropion used for smoking intermediates, pesticide, appl
Slide 13: End users of our Products
End users of our Products 13
Slide 14: End-user industries
PHARMACEUTICALS NUTRACEUTICALS AGRO CHEMICALS CONSTRUCTION CHEMICALS DYES & PIGMENTS FLAVORS & FRAGRANCES
Slide 15: Competitive Advantages
Competitive Advantages 15
Slide 16: Eiko LifeSciences Competitive Advantages
Eiko Large and diverse array of products LifeSciences has the Strong relations with Manufacturing facilities following Diversified and Stable Customer Base Competitive Advantages: Strong Relations with Marquee Clients Experienced team with domain knowledge Established and stable relationship with su
Slide 17: Experienced Promoters, Board of Directors and KMPs
Experienced Promoters, Board of Directors and KMPs 17
Slide 18: Board of Directors and Promoters
Operations of the Company are being professionally managed by a team of experienced technocrats under guidance from Board of Directors/ Promoters ➢ CA Laxmikant Kabra (Chairman, Promoter Director) ➢ Mr. Bhavesh Dhirajlal Tanna (Promoter Director) ➢ Mr. Umesh More (Executive Director) ➢ Ms. Kajal Kot
Slide 19: Thanks!
Thanks! Any questions? You can find us at: business@eikolifesciences.com 19
Eiko Lifesciences — Q3 FY2020-21 Earnings Presentation on 6ix